CTLA-4 — Drug Target

All drugs that target CTLA-4 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

CTLA-4-directed Blocking Antibody [EPC] · CTLA-4 inhibitor · Anti-CTLA4 monoclonal antibody · CTLA-4 inhibitor (in combination with PD-1 inhibitor)

Marketed (2)

• Imjudo · AstraZeneca · CTLA-4-directed Blocking Antibody [EPC] · Oncology
  Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth.
• tremelimumab (treme) · AstraZeneca · CTLA-4 inhibitor · Oncology
  Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.

Phase 3 pipeline (8)

• tremelimumab (anti-CTLA4) · AstraZeneca · Anti-CTLA4 monoclonal antibody · Oncology
  Tremelimumab is an anti-CTLA4 monoclonal antibody that blocks the CTLA-4 receptor, enhancing T-cell activation and proliferation.
• EU-sourced YERVOY® · Shanghai Henlius Biotech · CTLA-4 inhibitor · Oncology
  YERVOY (ipilimumab) blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
• RANCAD · TSH Biopharm Corporation Limited · CTLA-4 inhibitor · Oncology
  RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses.
• Tremelimumab (Regimen 2) · AstraZeneca · CTLA-4 inhibitor · Oncology
  Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
• Tremelimumab (Regimen 1) · AstraZeneca · CTLA-4 inhibitor · Oncology
  Tremelimumab is a monoclonal antibody that targets CTLA-4, a protein that helps regulate the immune system.
• JS004 in combination with toripalimab · Shanghai Junshi Bioscience Co., Ltd. · CTLA-4 inhibitor (in combination with PD-1 inhibitor) · Oncology
  JS004 is a CTLA-4 inhibitor that blocks immune checkpoint signaling, and when combined with toripalimab (a PD-1 inhibitor), it provides dual checkpoint blockade to enhance anti-tumor immune responses.
• Ipilimumab Injection · Federation Francophone de Cancerologie Digestive · CTLA-4 inhibitor · Oncology
  Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
• Ipilimumab infusion · The Netherlands Cancer Institute · CTLA-4 inhibitor · Oncology
  Ipilimumab blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.

Phase 2 pipeline (2)

• HF10 plus Ipilimumab · Takara Bio Inc. · CTLA-4 inhibitor · Oncology
  HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells.
• INCMGA00012 · Providence Health & Services · CTLA-4 inhibitor · Oncology
  INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity.